Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 17/20 | 0.66 |
| ▸ | PPARG | P37231 | 15/20 | 0.66 |
| ▸ | CTRC | Q99895 | 1/20 | 0.62 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21057121 | 0.89 | PPARA (0.71) | PPARAPPARG | |
| SCHEMBL21057124 | 0.89 | PPARA (0.71) | PPARAPPARG | |
| SCHEMBL30575143 | 0.88 | PPARA (0.69) | PPARAPPARGCTRC | |
| SCHEMBL21992490 | 0.88 | PPARA (0.50) | PPARAPPARGCTRCNR4A2MAOA | |
| SCHEMBL21992512 | 0.88 | LMNA (0.51) | PPARAPPARGCTRCNR4A2MAOA | |
| SCHEMBL21991819 | 0.86 | PPARA (0.48) | PPARAPPARGCTRCNR4A2MAOA | |
| SCHEMBL21992510 | 0.85 | PPARA (0.66) | PPARAPPARG | |
| SCHEMBL21991782 | 0.84 | CTRC (0.59) | PPARAPPARGCTRCMAOB | |
| SCHEMBL6545280 | 0.84 | PPARA (0.68) | PPARAPPARGCTRC | |
| SCHEMBL21991742 | 0.83 | PPARA (0.63) | PPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220142961-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-05-12 | — | — | US | disclosed |
| US-11318111-B2 | CCL5 inhibitors | LAPKO INC (US) | 2022-05-03 | — | — | US | disclosed |
| US-20210196665-A1 | CCL5 Inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
| US-5679801-A | ANTIINFLAMMATORY AGENTS, ANTIASTHMATICS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1997-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220142961-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | PPARA 806/4885PPARG 1583/4885CTRC 2261/4885 |
| US-20210196665-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | PPARA 806/4885PPARG 1583/4885CTRC 2261/4885 |
| US-11318111-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | PPARA 806/4885PPARG 1583/4885CTRC 2261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.